Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.60 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069869 | 1.00 | CHRM1 (0.65) | CHRM1PDE4ACA12CA1CA2 | |
| Mabuprofen SCHEMBL51633 | 0.86 | CHRM1 (0.67) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL12613755 | 0.85 | CHRM1 (0.65) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL12608940 | 0.84 | CA12 (0.64) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL15343987 | 0.84 | CA12 (0.64) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL15369139 | 0.84 | CA12 (0.64) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL24045921 | 0.84 | TRPV1 (0.64) | CHRM1PDE4ACA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL12501502 | 0.84 | CHRM1 (0.63) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL12613829 | 0.84 | CHRM1 (0.63) | CHRM1PDE4ACA12CA1CA2 | |
| SCHEMBL16190249 | 0.84 | TRPV1 (0.64) | CHRM1PDE4ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430020-B1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPÉ FARMACEUTICI S P A (IT) | 2016-03-02 | — | — | EP | disclosed |
| US-20040266870-A1 | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-12-30 | — | — | US | disclosed |
| EP-1430020-A1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003029187-A1 | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266870-A1 | Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them | C3AR1, IL5, AP1G1 | CHRM1 673/4885PDE4A 3154/4885CA12 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.